Precision Psychiatry Market Report 2026

Precision Psychiatry Market Overview

• Precision Psychiatry market size has reached to $4.99 billion in 2025 • Expected to grow to $9.81 billion in 2030 at a compound annual growth rate (CAGR) of 14.4% • Growth Driver: Increasing Prevalence Of Mental Health Disorders Fueling The Growth Of The Market Due To Rising Psychological Distress And Higher Diagnosis Rates • Market Trend: Software-Based Interventions Enhance Treatment Adherence • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Precision Psychiatry Market?

Precision psychiatry is a data-driven approach that combines genetic, neurobiological, behavioral, and environmental information to understand individual disease mechanisms. Its primary purpose is to improve diagnostic accuracy, guide personalized treatment, and enhance outcomes by reducing trial-and-error prescribing. It supports preventive strategies through personalized risk assessment and continuous monitoring. The main therapeutic approaches in precision psychiatry are pharmacotherapy, psychotherapy, neurostimulation, digital therapeutics, and combination therapies. Pharmacotherapy in precision psychiatry refers to the use of personalized medication strategies based on an individual’s genetic, biochemical, and clinical profile to treat mental health disorders. It utilizes different technologies such as genetic testing, biomarker analysis, brain imaging techniques, wearable devices, and artificial intelligence and machine learning solutions, and is indicated for disorders including depression, anxiety disorders, bipolar disorder, schizophrenia, and post-traumatic stress disorder (PTSD). It finds applications in diagnosis, treatment, and research, serving end users such as clinics, hospitals, research institutes, pharmaceutical companies, and home care settings.

What Is The Precision Psychiatry Market Growth Forecast?

The precision psychiatry market size is expected to see rapid growth in the next few years. It will grow to $9.81 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to increasing investments in precision medicine platforms, rising adoption of ai-enabled diagnostics, expansion of digital mental health solutions, growing demand for personalized psychiatric care, increasing focus on preventive mental health strategies. Major trends in the forecast period include increasing adoption of biomarker-guided treatment pathways, rising use of digital phenotyping tools, growing integration of genetic and neuroimaging data, expansion of AI-driven clinical decision support, enhanced focus on personalized mental health monitoring.

Global Precision Psychiatry Market Segmentation

1) By Therapeutic Approaches: Pharmacotherapy, Psychotherapy, Neurostimulation, Digital Therapeutics, Combination Therapies 2) By Technology: Genetic Testing, Biomarker Analysis, Brain Imaging Techniques, Wearable Devices, Artificial Intelligence And Machine Learning Solutions 3) By Disorders: Depression, Anxiety Disorders, Bipolar Disorder, Schizophrenia, Post-Traumatic Stress Disorder (PTSD) 4) By Application: Diagnosis, Treatment, Research 5) By End User: Clinics, Hospitals, Research Institutes, Pharmaceutical Companies, Home Care Settings Subsegments: 1) By Pharmacotherapy: Antidepressant Medications, Antipsychotic Medications, Mood Stabilizers, Anxiolytic Medications, Stimulant Medications 2) By Psychotherapy: Cognitive Behavioral Therapy, Interpersonal Therapy, Psychodynamic Therapy, Dialectical Behavior Therapy, Mindfulness-Based Therapy 3) By Neurostimulation: Transcranial Magnetic Stimulation, Electroconvulsive Therapy, Vagus Nerve Stimulation, Deep Brain Stimulation, Transcranial Direct Current Stimulation 4) By Digital Therapeutics: Mobile Application-Based Therapy, Virtual Reality Therapy, Web-Based Cognitive Behavioral Programs, Remote Patient Monitoring Tools, Artificial Intelligence-Guided Interventions 5) By Combination Therapies: Pharmacotherapy And Psychotherapy Combination, Pharmacotherapy And Neurostimulation Combination, Pharmacotherapy And Digital Therapeutics Combination, Psychotherapy And Neurostimulation Combination, Multimodal Precision Treatment Programs

What Is The Driver Of The Precision Psychiatry Market?

The increasing prevalence of mental health disorders is expected to propel the growth of the precision psychiatry market going forward. Mental health disorders refer to a wide range of conditions, such as depression, anxiety, and bipolar disorder, that affect mood, thinking, and behavior. Mental health disorders are rising as more individuals experience psychological distress due to social, economic, and environmental pressures, along with improved screening and public awareness that lead to higher diagnosis rates. Precision psychiatry addresses mental health disorders by enabling data-driven, personalized treatment strategies that improve accuracy in diagnosis and therapeutic outcomes. For instance, in November 2023, according to NHS England, the UK-based publicly funded national health authority, the rate of a probable mental disorder for those aged 20 to 23 years was raised from 18.7% in 2022 to 21.6% in 2023. Therefore, the increasing prevalence of mental health disorders is driving the growth of the precision psychiatry industry.

Key Players In The Global Precision Psychiatry Market

Major companies operating in the precision psychiatry market are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Pfizer Inc., AbbVie Inc., AstraZeneca plc, Novartis AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Otsuka Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Illumina Inc., ARUP Laboratories Inc., Sumitomo Dainippon Pharma Company Limited, QIAGEN N.V., Neurocrine Biosciences Inc., Tempus Labs Inc., Myriad Genetics Inc., MedGenome Labs Ltd., Genomind Inc.

Global Precision Psychiatry Market Trends and Insights

Major companies operating in the precision psychiatry market are focusing on developing new therapies, such as prescription digital therapeutics, to enable personalized and data-driven treatment for psychiatric disorders. A prescription digital therapeutic is a clinician-prescribed, software-based medical intervention that delivers evidence-based behavioral therapy modules through a mobile device to enhance symptom improvement and treatment adherence. For instance, in August 2024, Otsuka Precision Health Inc., a US-based precision health subsidiary of Otsuka Holdings, and Click Therapeutics Inc., a US-based digital therapeutics company, launched Rejoyn, the first and only prescription digital therapeutic cleared by the United States Food and Drug Administration (FDA) for the adjunctive treatment of major depressive disorder (MDD) symptoms. The product delivers a six-week cognitive-emotional training program combining the emotional faces memory task with cognitive behavioral therapy (CBT)–based skill modules and supports digital prescribing, patient engagement, and remote monitoring. The launch of Rejoyn represents a significant milestone in Precision Psychiatry, demonstrating how digital therapeutics can complement pharmacological treatments to deliver personalized care. It also paves the way for broader adoption of software-based interventions that integrate real-time patient data to optimize treatment outcomes and adherence.

What Are Latest Mergers And Acquisitions In The Precision Psychiatry Market?

In January 2025, Johnson & Johnson, a US-based pharmaceutical company, acquired Intra-Cellular Therapies Inc. for approximately $14.6 billion. Through this acquisition, Johnson & Johnson seeks to expand its portfolio of innovative psychiatric therapeutics and leverage Intra-Cellular’s expertise in mechanism-based drug development for central nervous system disorders. Intra-Cellular Therapies Inc. is a US-based company developing targeted neuropsychiatric therapies aligned with Precision Psychiatry.

Regional Outlook

North America was the largest region in the precision psychiatry market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Precision Psychiatry Market?

The precision psychiatry market includes revenues earned by entities through psychiatric assessment, personalized treatment planning, remote monitoring, data analytics, and clinical decision support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Precision Psychiatry Market Report 2026?

The precision psychiatry market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the precision psychiatry industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.